<DOC>
	<DOCNO>NCT00652379</DOCNO>
	<brief_summary>The purpose study investigate co-treatment acromegalic patient , beforehand consider well-controlled SA monotherapy , pegvisomant SA improve insulin sensitivity glucose tolerance , effect co-treatment obtained neutral cost compare SA mono therapy . Second investigate body composition , substrate metabolism , symptom , intrahepatic intramyocellular fat .</brief_summary>
	<brief_title>Co-treatment With Pegvisomant Somatostatin Analogue ( SA ) SA-responsive Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age &gt; 18 Diagnosed acromegaly Safe anticonceptive fertile woman Well control somatostatin analog ( serum IGFI within normal range nadir GH &lt; 0.5 Âµg/l . ) Pregnancy Liver disease Diabetes mellitus type I Magnetic electronic implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Glucose tolerance</keyword>
	<keyword>Body composition</keyword>
	<keyword>Growth Hormone</keyword>
</DOC>